Which situation describes potential observer bias in an experimental process?
A) Dr. Jones is evaluating cancer patients for their responses to a new therapeutic drug. She knows which patients are receiving the placebo and which are receiving the drug.
B) Mr. Bromley is conducting a survey of weight loss for his professor. He asks each student in the study the same questions.
C) Ms. Bradley is an outside consultant who is conducting a health and wellness survey for a pharmaceutical company. She does not know the name of the company nor does she know the name of the drug being tested during the survey.
D) Dr. Postgate is analyzing biopsy samples from rats that have been given either a placebo or an experimental drug believed to reduce inflammation. Each sample is identified by a code number so that Dr. Postgate cannot tell which treatment the rats received.
A
You might also like to view...
An enzyme catalyzes a substrate into a final product. When the concentration of the final product is high enough, it binds to a regulatory site on the enzyme
This binding at the regulatory site changes the shape of the enzyme, which prevents it from binding the substrate and prevents formation of more final product. This is an example of a(n) _______________. A. posttranslational modification B. allosteric enzyme C. translational repressor D. methylation
“Genetic fingerprinting” is based on unique
a. nucleotide base pairing b. types of nucleotides c. differences in tandem repeats. d. ratios of purines to pyrimidines e. bonding patterns between nucleotides
How will DNA replication be affected if DNA polymerase I has a mutation that inactivates 5'-to-3' exonuclease activity?
What will be an ideal response?
When an enzyme is degraded into its monomeric structural units, the monomers will be
a) monosaccharides b) fatty acids c) nucleotides d) amino acids